Ocugen, Inc. (OCGN)
Nasdaq · Common stock · Biological Products, (no Diagnostic Substances)
As of Oct 21, 3:20 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
OCGN trades thinly or has a short history, so some panels below have little to show.
Follow OCGN in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on OCGN and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
OCGN at a glance
Key statistics
$275.53M
Market capitalization
- Previous close
- $0.8125
- Open
- $0.8300
- Day range
- $0.7910 – $0.8300
- Volume
- 3.26M
- Average volume (30 sessions)
- 8.77M
- Shares outstanding
- 339.11M
- Earnings per share
- $(0.19)
- Price / sales
- 57.5
- Beta (1 year, vs SPY)
- 1.55
Where the price sits in its year
52-week range
1% of the range
- Below the 52-week high
- -70.4%
- Above the 52-week low
- +3.4%
Completed sessions through Oct 20, 2026
Technical snapshot
Below its 50-day and 200-day averages
- 20-day average
- $0.9535-14.8%
- 50-day average
- $1.13-28.4%
- 200-day average
- $1.46-44.5%
In the band below 30 that convention calls oversold. Weak trends can stay there for weeks.
-8.2%
1 week
-21.1%
1 month
-37.0%
3 months
-39.8%
Year to date
-49.2%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with OCGN
OCGN on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on OCGN.
See the plans →
Every planScreen names like OCGN
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on OCGN
Put OCGN on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on OCGN
See whether there is an open premium alert on OCGN, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
OCGN headlines
- Ocugen to Participate in Upcoming September Investor and Industry Conferences
GlobeNewswire Inc. · Aug 25, 2026
- Ocugen to Participate in Upcoming July Industry Conferences
GlobeNewswire Inc. · Jul 1, 2026
- Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
GlobeNewswire Inc. · Jan 13, 2026
- Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants
GlobeNewswire Inc. · Aug 12, 2025
- Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
GlobeNewswire Inc. · Aug 8, 2025
- Ocugen (OCGN) Shares Slide Following Merger Agreement: What's Going On?
Benzinga · Jun 23, 2025
- Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results
GlobeNewswire Inc. · May 2, 2025
- Attention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); MGP Ingredients, Inc. (NASDAQ: MGPI); and Ocugen, Inc. (NASDAQ: OCGN): Grabar Law Office Investigates Claims on Your Behalf
GlobeNewswire Inc. · Mar 6, 2025
SEC Form 4, most recent first
Insider filings
Musunuri Shankar
−57.3K
Chief Executive Officer, Director · Open-market sale
$54.40K · Oct 9, 2026
Musunuri Shankar
−468.7K
Chief Executive Officer, Director · Open-market sale
$445.29K · Oct 9, 2026
Musunuri Shankar
−57.3K
Chief Executive Officer, Director · Open-market sale
$64.14K · Sep 9, 2026
Musunuri Shankar
−468.7K
Chief Executive Officer, Director · Open-market sale
$524.97K · Sep 9, 2026
Johnson-Greene Treerita Essalima
+21.0K
Chief Financial Officer · Open-market purchase
$25.83K · Jun 15, 2026
Kompella Uday
+170.1K
Director · Grant or award
· Jun 11, 2026
Coleman Blaise
+170.1K
Director · Grant or award
· Jun 11, 2026
Castillo Kirsten
+170.1K
Director · Grant or award
· Jun 11, 2026
About Ocugen, Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Biological Products, (no Diagnostic Substances)
- Headquarters
- Malvern, PA
- Employees
- 116
- Listed since
- Dec 3, 2014
- Website
- ocugen.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.